Cyberounds Logo
February 09, 2012 | LOGIN | REGISTER | HELP | 
email a friend print Bookmark and Share
Systemic Lupus Erythematosus (SLE) - Part I: New Treatments for Mild SLE
CME credit is no longer available for this conference.
Elena Peeva, M.D., M.Sc., Gisele Zandman-Goddard, M.D., and Peter Barland, M.D.

Dr. Peeva is an Instructor of Medicine and Attending Physician at the Albert Einstein College of Medicine and Attending Physician at Montefiore Medical Center, NY, and Dr. Zandman-Goddard is an Instructor of Medicine and Attending Physician at Sheba Medical Center, Israel.

Drs. Peeva, Zandman-Goddard and Barland report no commercial conflicts of interest.


Release Date: 01/03/2001
Termination Date: 01/03/2004

Estimated time to complete: 1 hour(s).

Albert Einstein College of Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
 
Learning Objectives
Upon completion of this Cyberounds®, the participant should be able to:
  • Discuss the current prognosis of systemic lupus erythematosus (SLE)
  • List the general measures used to prevent flares of SLE
  • Discuss the precautions in the uses of NSAIDs and antimalarial therapy in SLE
  • Describe the results of recent trials with bromocriptine and DHEA in SLE.

 
This conference may include discussion of commercial products and services.

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
 
Please click below to accept the terms of this CME activity